Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002378 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 825
- Enrollment target
NCT00002378: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00002378 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 825 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002378, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 825 participants
- Enrollment target
Study Summary
To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (\< 400 copies/ml) at week 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment. To collect safety data on the treatment regimens. AS PER AMENDMENT 12/12/97: To compare the virologic response of Fortovase (FTV) (Saquinavir) Soft Gel Capsule (SGC) tid plus nucleoside reverse transcriptase inhibitors (NRTIs) versus FTV bid plus NRTIs. Further, to compare the virologic response of FTV tid plus NRTIs versus FTV bid plus Nelfinavir bid plus a NRTI with respect to: the percentage of patients whose plasma HIV-1 RNA level falls below the Amplicor assay level of detection (\< 400 copies/ml) at week 24 and week 48.
Interventions
- DRUG Lamivudine
- DRUG Ritonavir
- DRUG Nelfinavir mesylate
- DRUG Delavirdine mesylate
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Phase | Phase 3 |
What the finished NCT00002378 record still lists
NCT00002378 is an interventional study that assigns participants to a tested intervention. The registered 825 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00002378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002378 about?
NCT00002378 is a clinical study titled "A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients". To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (\< 400 copies/ml) at week 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment. To collect safety data on the treatment regimens. AS P...
What is the current status of trial NCT00002378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 825 participants.
What interventions are being tested in trial NCT00002378?
The interventions under investigation include: Lamivudine (DRUG), Ritonavir (DRUG), Nelfinavir mesylate (DRUG), Delavirdine mesylate (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002378?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002378's enrollment target sits among peer trials
825 400th of 2000 higher than 1,599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
- NCT07318077 · 825 participants · NA
Radicle GI Health DBG: A Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes